DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
>
> This Story

Forward Printable StoryPrint Comment

 

Oncology Homepage

First patient treated with RayPilot in Turkey

Varian Halcyon treatment system receives Shonin approval

Baptist Hospital's Miami Cancer Institute awarded cancer research and education grant by IBA

ASCO expands TAPUR study enrollment after promising initial treatment outcomes seen

Delta4 Discover transmission detector approved for use by Varian Medical Systems on TrueBeam and Clinac systems

Intraoperative imaging systems market to reach $3.4 billion by 2024

Varian to showcase technologies for enhancing oncology care coordination at AONN+ Conference

United States proton therapy market is expected to reach nearly $1 billion, potentially $7 billion by 2025

Critical prostate cancer research funding saved

iCAD's Xoft clinical research selected as 'Best of ASTRO 2017'

New interim results support Imagio Opto-Acoustic (OA) breast imaging system's potential to reduce negative biopsies

Press releases may be edited for formatting or style
SAN ANTONIO, Sept. 24, 2016 /PRNewswire/ -- Seno Medical Instruments, Inc. (Seno Medical), the company pioneering the development of opto-acoustic technology as a tool to improve the process of diagnosing breast cancer, announced today interim results from the company's multicenter, European MAESTRO post-market surveillance and clinical follow-up study. The results demonstrate the potential of its Imagio® opto-acoustic (OA) breast imaging system to provide physicians with vital information needed to determine whether or not a suspicious mass is cancerous, with the goal of reducing the rate of negative biopsies. The data were presented at a clinical symposium at the Annual Scientific Meeting of the European Society of Breast Imaging (EUSOBI), the second largest conference in the world dedicated to breast cancer imaging, on September 24, 2016 in Paris.

"The interim results from MAESTRO add to the growing body of clinical evidence showing that the Imagio opto-acoustic diagnostic tool increases physicians' confidence when differentiating and classifying malignant and benign breast tissue," said the study's principal investigator Ruud Pijnappel, MD, PhD, Radiologist, University Medical Center, Utrecht, NL, who presented the interim analysis. "The improved accuracy that is possible with this technology could help women avoid painful biopsy procedures that sometimes follow false-positive diagnoses."

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs



There are over 1.6 million biopsies performed annually1 and recent reported data noted an 81% "false positive" rate of biopsy procedures – the portion of biopsies that do not lead to breast cancer surgery.2 Seno Medical's Imagio breast imaging system, which received its CE Mark in 2014, has the potential to reduce negative biopsies by 43%. Seno Medical is targeting their PMA submission for the Imagio system to the U.S Food and Drug Administration by the end of 2016.

MAESTRO, a controlled, multi-center, observational, post-market surveillance and clinical follow-up study, was designed to assess the diagnostic value (specificity and sensitivity) of Opto-Acoustics to conventional diagnostic ultrasound (CDU) in suspicious masses classified as BI-RADS 4a and 4b. Investigators first performed CDU to reach a diagnosis and decision to biopsy followed by an Imagio OA examination. Two hundred female subjects with undiagnosed suspicious masses enrolled in the study.

The interim analysis of 78 subjects found that following the use of Imagio system, radiologists downgraded BI-RADS categories of the internal ultrasound control-classified BI-RADS 4a masses to BI-RADS 3 or 2 in 75% of cases, and BI-RADS 4b masses to either BI-RADS 3 or 2 in 37.5% of cases. The interim results also showed that Imagio OA also increased specificity to over 43%, with no significant loss in sensitivity. Importantly, clinicians were able to reduce the rate of false-positive diagnoses by 20% for the last 48 subjects evaluated in the study.
  Pages: 1 - 2 - 3 >>

Oncology Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2017 DOTmed.com, Inc.
版权所有